STAT editors and reporters review the widespread impact of grant cuts, layoffs and policy changes — and also discuss recent drug launches.

Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Indeed, shares of the three biggest pharmaceutical companies based on market cap -- AbbVie (NYSE: ABBV),

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on tariffs on the industry. Trump's Department of Commerce is looking into what it calls national security threats from overseas drug manufacturing,

Business leaders from major Hoosier companies say they are trying to navigate the uncertain trade environment created by President Donald Trump’s fluctuating tariff policy by exploring alternative options and being vocal about problems when they arise.

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, predicted that though Trump had spared the industry with tariffs, that wouldn't last much longer.